Loading...
  • oral
  • After the oral administration of 200 mg of Disopyramide to 10 cardiac patients with borderline to moderate heart failure, the time to peak serum concentration of 2.3 ± 1.5 hours (mean ± SD) was increased, and the mean peak serum concentration of 4.8 ± 1.6 mcg/mL was higher than in healthy volunteers. (drugs.com)
  • In a second study of the oral administration of Disopyramide to 7 patients with heart disease, including left ventricular dysfunction, the mean plasma half-life was slightly prolonged to 7.8 ± 1.9 hours (range of 5 to 9.5 hours). (drugs.com)
  • A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt. (thefreedictionary.com)
  • Serum
  • We have evaluated the influence of several factors on the binding of disopyramide to protein in human serum using a new ultrafiltration system and the enzyme multiplied immunoassay technique (EMIT) for disopyramide immuno-assay. (ebscohost.com)
  • renal
  • In six patients with impaired renal function (creatinine clearance less than 40 mL/min), Disopyramide half-life values were 8 to 18 hours. (drugs.com)
  • symptoms
  • Indeed, for relief of resistant symptoms, the European Society of Cardiology 5 and American Heart Association/American College of cardiology 6 guidelines rate disopyramide with a class I and IIa recommendation, respectively. (ahajournals.org)
  • effect
  • Controlled-release disopyramide offers many potential advantages over the standard formulation for improved patient compliance, possible reduction of concentration-related adverse effects, and predictability of pharmacologic effect. (ebscohost.com)
  • Rifampicin and decrease the concentration and effect of disopyramide. (medicinehow.com)